PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas

Inclusion Criteria: * Pts with MG histologically confirmed at diagnosis, who were treated previously with conventional external beam radiation \& with or without chemotherapy, \& have stable disease, recurrence or relapse at the time of enrollment. * Age \> or = to 18 years. * Patients who have had previous surgical resection(s) are eligible. * Interval of at least 3 weeks between prior surgical resection, 2 weeks between prior radiotherapy, or 4 weeks between prior chemotherapy, unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy. * Karnofsky performance score \> or = to 60%. * Adequate hematologic, renal \& liver function as demonstrated by lab values performed within 14 days, inclusive, prior to administration of chemotherapy: * ANC \> or = to 1500/mm3 * Platelet count \> or = to 100,000/mm3 * Hemoglobin \> or = to 10 gm/dL * BUN and serum creatinine \<1.5 times upper limit of lab normal * Total serum bilirubin \<1.5 times upper limit of lab normal * SGOT \<2.5 times upper limit of lab normal * Patients must have recovered from any effects of major surgery. * Patients must have life expectancy of greater than 12 weeks. * Patients or legal guardian must give written, informed consent. Exclusion Criteria: * Patients requiring immediate radiation therapy. * Patients who have not recovered from surgery. * Patients who are not neurologically stable for 2 weeks prior to study entry. * Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics. * Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction). * Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed. * Known HIV positivity or AIDS-related illness. * Pregnant or nursing women. * Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 72 hours prior to administration of study drug and be practicing medically approved contraceptive precautions. * Men who are not advised to use an effective method of contraception. * Patients taking immuno-suppressive agents other than prescribed corticosteroids. * Patients previously treated with farnesyl transferase inhibitors. * Patients with significant QTc prolongation (\>500 msec)as evaluated by an EKG. * Patients having presented prior disease progression on TEMODAR. * Patients having presented any grade 4 hematologic toxicity or grade 3 or 4 non-hematologic toxicity on TEMODAR in the past.